



January 24, 2023

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex Bandra (East) <u>Mumbai - 400 051</u> <i>Stock Code : INDOCO-EQ</i>	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai - 400 001</u> <i>Stock Code : 532612</i>
---	---

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 24th January, 2023

Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 24th January, 2023 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 along with the Limited Review Report issued by the Statutory Auditor of the Company.

Please find enclosed copies of the following:

- Unaudited Standalone and Consolidated Financial Results as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Limited Review Certificate issued by our Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants.
- Press Release

The Board Meeting commenced today at 10: 45 a.m. and concluded at 12:00 noon.

You are requested to kindly take the same on record

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

Ramanathan Hariharan
Company Secretary & Head- Legal



INDOCO REMEDIES LIMITED

Indoco House, 166, C.S.T. Road, Kalina, Santacruz (E), Mumbai 400098, India.
Tel. No.: +91 22 6287 1000 / 6879 1250 ■ CIN: L85190MH1947PLC005913

www.indoco.com



INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098.
Tel: +91-22-68791250/62871000 Email: compliance.officer@indoco.com
Website: www.indoco.com CIN: L85190MH1947PLC005913

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2022

(Rs. In Lakhs)

Sl.No.	Particulars	Quarter ended 31.12.2022 (Unaudited)	Quarter ended 30.09.2022 (Unaudited)	Quarter ended 31.12.2021 (Unaudited)	Nine months ended 31.12.2022 (Unaudited)	Nine months ended 31.12.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	41,059	40,460	34,863	1,21,008	1,10,243	1,50,270
	(b) Other Operating Income	(1,195)	2,809	913	2,915	2,841	3,702
	Total Income from Operations (Net) (a+b)	39,864	43,269	35,776	1,23,923	1,13,084	1,53,972
2	Other Income	37	34	16	184	203	232
3	Total Income (1+2)	39,901	43,303	35,792	1,24,107	1,13,287	1,54,204
4	Expenses						
	(a) Cost of materials consumed	11,655	11,501	8,004	31,962	26,226	39,371
	(b) Purchases of stock-in-trade	1,452	2,494	3,186	6,527	8,355	8,943
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(72)	(1,256)	(319)	494	(2,049)	(2,630)
	(d) Employee Benefits expense	8,176	7,995	7,164	24,477	22,144	29,495
	(e) Finance Costs	701	525	381	1,639	1,110	1,414
	(f) Depreciation and Amortization expense	1,716	1,565	1,922	5,291	6,091	7,895
	(g) Research & Development Expense	1,983	1,886	1,709	5,690	5,493	7,455
	(h) Other Expenses	10,505	11,873	8,692	32,701	28,262	38,638
	Total Expenses	36,116	36,583	30,739	1,08,781	95,632	1,30,581
5	Profit before Tax (3-4)	3,785	6,720	5,053	15,326	17,655	23,623
6	Tax Expenses						
	- Current	821	1,924	1,572	4,285	6,940	9,323
	- Deferred	177	(168)	184	(558)	(700)	(734)
	- MAT Credit Adjustments	-	-	-	-	-	(418)
	Total Tax Expenses	998	1,756	1,756	3,727	6,240	8,171
7	Profit for the period (5-6)	2,787	4,964	3,297	11,599	11,415	15,452
8	Other Comprehensive Income						
a	i) Items that will not be reclassified to profit and loss	(150)	(150)	(30)	(450)	(90)	(819)
	ii) Income tax on relating to this item	53	53	11	158	32	286
b	i) Items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(97)	(97)	(19)	(292)	(58)	(533)
9	Total Comprehensive income for the year (7+8)	2,690	4,867	3,278	11,307	11,357	14,919
10	Paid up Equity Share Capital (Face value Rs. 2/- each)	1,843	1,843	1,843	1,843	1,843	1,843
11	Other Equity						88,587
12	Earnings per share (of Rs. 2/- each)						
	(a) Basic- in Rs.	3.02	5.39	3.58	12.59	12.39	16.77
	(b) Diluted- in Rs.	3.02	5.39	3.58	12.59	12.39	16.77

Notes:

- The unaudited Standalone Results for the Quarter and Nine Months ended 31st December, 2022 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 24th January, 2023. The Statutory Auditors have expressed an Unmodified Limited Review opinion on these unaudited Standalone Financial Results.
- The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.
- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(Rs. In Lakhs)

Net Sales and Income from Operations	Quarter ended 31.12.2022 (Unaudited)	Quarter ended 30.09.2022 (Unaudited)	Quarter ended 31.12.2021 (Unaudited)	Nine months ended 31.12.2022 (Unaudited)	Nine months ended 31.12.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
India	21,423	22,470	19,324	64,559	64,128	84,625
Outside India	19,636	17,990	15,539	56,449	46,115	65,645
Total	41,059	40,460	34,863	1,21,008	1,10,243	1,50,270

- The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2022.
- There are no Exceptional Items

By Order of the Board
For Indoco Remedies Ltd



Aditi Panandikar
Managing Director

Place : Mumbai
Date : January 24, 2023

Independent Auditors' Limited Review Report on quarterly and year-to-date unaudited standalone financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
Indoco Remedies Limited

- 1 We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Indoco Remedies Limited ("the Company") for the quarter ended 31 December 2022 and year to date results for the period ended 1 April 2022 to 31 December 2022 being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 as amended ("Listing Regulations")
- 2 This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



gokhale & sathe (regd.)

chartered accountants
308/309, Udyog Mandir No. 1,
7-C, Bhagoji Keer Marg,
Mahim, Mumbai 400 016
Tel :91 22 43484242
Email – office@gokhalesathe.in

Independent Auditors' Limited Review Report on quarterly and year-to-date unaudited standalone financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

- 4 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gokhale & Sathe,
Chartered Accountants
Firm Registration No.: 103264W



Tejas Parikh
Partner
Membership Number - 123215
UDIN: -23123215BGQKZT4780
Place: Mumbai
Date: 24th January 2023



INDOCO REMEDIES LIMITED
 Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098.
 Tel: +91-22-68791250/62871000 Email: compliance.officer@indoco.com
 Website: www.indoco.com CIN: L85190MH1947PLC005913

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2022

Sl.No.	Particulars	(Rs. In Lakhs)					
		Quarter ended 31.12.2022 (Unaudited)	Quarter ended 30.09.2022 (Unaudited)	Quarter ended 31.12.2021 (Unaudited)	Nine months ended 31.12.2022 (Unaudited)	Nine months ended 31.12.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	41,115	40,495	34,887	1,21,131	1,10,322	1,50,373
	(b) Other Operating Income	(1,195)	2,809	913	2,915	2,841	3,702
	Total Income from Operations (Net) (a+b)	39,920	43,304	35,800	1,24,046	1,13,163	1,54,075
2	Other Income	36	35	16	184	203	233
3	Total Income (1+2)	39,956	43,339	35,816	1,24,230	1,13,366	1,54,308
4	Expenses						
	(a) Cost of materials consumed	11,655	11,501	8,004	31,962	26,230	39,374
	(b) Purchases of stock-in-trade	1,452	2,494	3,186	6,527	8,355	8,943
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(72)	(1,256)	(319)	494	(2,049)	(2,630)
	(d) Employee Benefits expense	8,213	8,034	7,193	24,589	22,236	29,625
	(e) Finance Costs	701	525	381	1,639	1,110	1,414
	(f) Depreciation and Amortization expense	1,717	1,565	1,922	5,292	6,091	7,896
	(g) Research & Development Expense	1,983	1,886	1,709	5,690	5,493	7,456
	(h) Other Expenses	10,485	11,860	8,682	32,649	28,218	38,573
	Total Expenses	36,134	36,609	30,758	1,08,842	95,684	1,30,651
5	Profit before Tax (3-4)	3,822	6,730	5,058	15,388	17,682	23,657
6	Tax Expenses						
	- Current	830	1,926	1,576	4,301	6,947	9,330
	- Deferred	177	(169)	185	(558)	(700)	(735)
	- MAT Credit Adjustments	-	-	(2)	-	-	(418)
	Total Tax Expenses	1,007	1,757	1,759	3,743	6,247	8,177
7	Profit for the period (5-6)	2,815	4,973	3,299	11,645	11,435	15,480
8	Share in Profit / (Loss) of Associates	(1)	-	-	(1)	-	-
9	Profit for the Year (7+8)	2,814	4,973	3,299	11,644	11,435	15,480
10	Other Comprehensive Income						
a	i) Items that will not be reclassified to profit and loss	(150)	(150)	(30)	(450)	(90)	(819)
	ii) Income tax on relating to this item	52	53	11	157	32	286
b	i) Items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(98)	(97)	(19)	(293)	(58)	(533)
11	Total Comprehensive income for the year (9+10)	2,716	4,876	3,280	11,351	11,377	14,947
	Profit attributable to:						
	Equity Shareholders of the Company	2,814	4,973	3,299	11,644	11,435	15,480
	Non-Controlling Interest	-	-	-	-	-	-
		2,814	4,973	3,299	11,644	11,435	15,480
	Other comprehensive income is attributable to:						
	Equity Shareholders of the Company	(98)	(97)	(19)	(293)	(58)	(533)
	Non-Controlling Interest	-	-	-	-	-	-
		(98)	(97)	(19)	(293)	(58)	(533)
	Total comprehensive income is attributable to:						
	Equity Shareholders of the Company	2,716	4,876	3,280	11,351	11,377	14,947
	Non-Controlling Interest	-	-	-	-	-	-
		2,716	4,876	3,280	11,351	11,377	14,947
12	Paid up Equity Share Capital (Face value Rs. 2/- each)	1,843	1,843	1,843	1,843	1,843	1,843
13	Other Equity	-	-	-	-	-	88,621
14	Earnings per share (of Rs. 2/- each)						
	(a) Basic- in Rs.	3.05	5.40	3.58	12.64	12.41	16.80
	(b) Diluted- in Rs.	3.05	5.40	3.58	12.64	12.41	16.80

Notes:

- The unaudited Consolidated Results for the Quarter and Nine Months ended 31st December, 2022 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 24th January, 2023. The Statutory Auditors have expressed an Unmodified Limited Review opinion on these unaudited Consolidated Financial Results.
- The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.
- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

Net Sales and Income from Operations	(Rs. In Lakhs)					
	Quarter ended 31.12.2022 (Unaudited)	Quarter ended 30.09.2022 (Unaudited)	Quarter ended 31.12.2021 (Unaudited)	Nine months ended 31.12.2022 (Unaudited)	Nine months ended 31.12.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
India	21,478	22,506	19,348	64,682	64,207	84,728
Outside India	19,637	17,989	15,539	56,449	46,115	65,645
Total	41,115	40,495	34,887	1,21,131	1,10,322	1,50,373

- The Consolidated Financial Results includes the Results of the following Companies

Name of the Company	% of Shareholding	Consolidated as
Xtend Industrial Designers & Engineers Pvt. Ltd.	100.00	Subsidiary
Indoco Remedies Czech S R O	100.00	Subsidiary
Indoco Remedies UK Ltd.	100.00	Subsidiary
Warren Remedies Private Limited	100.00	Subsidiary

- The Company has executed Share Purchase and Shareholders' Agreement and Power Purchase Agreement with Jalansar Wind Energy Private Limited & Kanakal Wind Energy Private Limited for acquisition of 26% stake each.
- The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2022.
- There are no exceptional items.



By Order of the Board
For Indoco Remedies Ltd

(Signature)

Aditi Panandikar
Managing Director

Place : Mumbai
Date : January 24, 2023

Independent Auditors' Limited Review Report on quarterly and year-to-date unaudited consolidated financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
Indoco Remedies Limited

- 1 We have reviewed the accompanying statement of unaudited consolidated financial results of Indoco Remedies Limited (hereinafter referred to as the "Holding Company"), its subsidiaries and associates (the Holding Company, its subsidiaries and associates together referred to as 'the Group') for the quarter ended 31 December 2022 and year to date results for the period 1 April 2022 to 31 December 2022, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 3 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



Independent Auditors' Limited Review Report on quarterly and year-to-date unaudited consolidated financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

1 This statement includes the standalone unaudited financial results of the following entities:

i) Subsidiaries

- a) Xtend Industrial Designers and Engineers Private Limited
- b) Indoco Remedies Czech SRO
- c) Indoco Remedies UK Limited
- d) Warren Remedies Private Limited

ii) Associates

- a) Jalansar Wind Energy Private Limited
- b) Kanakal Wind Energy Private Limited

2 Based on our review and procedures performed as stated in paragraph 3 above and based on consideration of the review reports of the auditors referred in paragraph no 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

3 We did not review the interim financial statements of the subsidiaries included in the statement of unaudited consolidated financial results, whose unaudited financial statements reflect total revenues of Rs. 55.23 lakhs and Rs. 122.72 lakhs and total net profit after tax of Rs. 27.60 lakhs and Rs. 46.37 lakhs for the quarter ended 31 December 2022 and for the period 1 April 2022 to 31 December 2022, respectively as considered in the Statement. This financial information has been reviewed by other auditors whose reports has been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of such matter.



gokhale & sathe (regd.)

chartered accountants

304/308/309, Udyog Mandir No. 1,

7-C, Bhagoji Keer Marg,

Mahim, Mumbai 400 016

Tel :91 22 43484242


Email – office@gokhalesathe.in

Independent Auditors' Limited Review Report on quarterly and year- to-date unaudited consolidated financial results of Indoco Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

- 4 The unaudited consolidated financial results also include the financial information of 2 foreign subsidiaries, which have not been reviewed, whose financial information reflect total revenues of Rs. 0.02 lakhs and Rs. 0.15 lakhs and net loss after tax Rs. 0.06 lakhs and Rs. 0.04 lakhs for the quarter ended 31 December 2022 and for the period 1 April 2022 to 31 December 2022, respectively as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.
- 5 The unaudited consolidated financial results also include the Group's share of loss after tax of Rs. 0.50 lakhs and Rs. 0.50 lakhs for the quarter ended 31 December 2022 and for the period 1 April 2022 to 31 December 2022 respectively, as considered in the Statement, in respect of an associates, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, at present these interim financial information/ financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of such matter.

For Gokhale & Sathe,
Chartered Accountants
Firm Registration Number: 103264W



Tejas Parikh
Partner



Membership Number: 123215
UDIN: 23123215BGQKZU1985
Place: Mumbai
Date: 24 January 2023



PRESS RELEASE

Indoco's Net Revenues grow at 18 % in Q3FY23

Mumbai, January 24, 2023: During the third quarter of FY 2022-23, revenues of Indoco Remedies grew by 17.8 % at Rs. 410.6 crores, as against Rs. 348.6 crores, same quarter last year. EBIDTA to net sales for the quarter is 15.0 % at Rs. 61.7 crores, compared to 21.1 % at Rs. 73.4 crores, same quarter last year. EBIDTA to net sales without impact of other operating income stands at 17.9 %. For the quarter, the Profit After Tax is at Rs. 27.9 crores.

For the 9-month period ended Dec'22, the revenues grew by 9.8 % at Rs. 1210.1 crores, as against Rs. 1102.4 crores, same period last year. EBIDTA to net sales for the period is 18.2 % at Rs. 220.7 crores, compared to 22.4 % at Rs.246.5 crores, same period last year. For the period, the Profit After Tax is at Rs. 116.0 crores.

Commenting on the third quarter FY23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, "A good performance in Domestic business and an excellent growth in Export business has allowed us to post good results this quarter".

For the quarter ended Dec'22, the financials are as under:

(Rs. in Crores)

Particulars	Oct'22-Dec'22	July'22-Sept'22	Oct'21-Dec'21
Net Revenues	410.6	404.6	348.6
EBIDTA	61.7	87.8	73.4
Operating Profit	57.3	85.7	67.5
Profit After Tax	27.9	49.6	33.0
EPS (Face value Rs.) 2/-)	3.03	5.39	3.58

For the 9-month period ended Dec'22, the financials are as under:

(Rs. in Crores)

Particulars	Apr'22-Dec'22	Apr'21-Dec'21
Net Revenues	1210.1	1102.4
EBIDTA	220.7	246.5
Operating Profit	208.3	229.4
Profit After Tax	116.0	114.1
EPS (Face value Rs.) 2/-	12.59	12.39

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 166 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexitin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Pramod Ghorpade

Mobile: 9619883225

E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com